⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market USA - English APAC - Traditional Chinese USA - English
prnewswire.com
AAPL
TSLA
XOM
MSFT
GOOGL
AMZN
NVDA
META
BRK.A
JPM
V
JNJ
PG
MA
HD
UNH
DIS
BAC
PFE
MRK
TMO
ABT
MDT
BMY
AMGN
GILD
AZN
LLY
BIIB
REGN
VRTX
ALGN
ISRG
TDOC
EXAS
ZLAB
SCHR
APT
BILI
HSAI
UBOT
TIGR
INSM
YXT
CCEL
IMUX
INCY
CRSP
EDIT
NTLA
SRPT
EXEL
LULU
CROX
NKE
CPRI
PVH
RL
URBN
M
KSS
TJX
BBY
ROST
DLTR
WMT
TGT
COST
SBUX
MCD
CMG
YUM
QSR
CBRL
TXRH
NDSN
TTWO
EA
NTDOY
SONY
MSGS
AMC
IMAX
RCL
CCL
NCLH
AAL
DAL
UAL
LUV
ALK
JBLU
SKX
ADBE
CRM
INTC
AMD
QCOM
AMAT
MU
NXPI
SNPS
CDNS
ASML
PAYX
ADP
NOW
CSCO
ORCL
IBM
HPQ
DELL
ACN
INFY
SAP
ERIC
NOK
STM
UL
PEP
KO
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Syndromic Multiplex Panels Market Strategies, Trends and Forecast 2025-2029: Cost Efficiency, Diagnostic Accuracy, Single-Visit Testing, and Pandemic-Driven Uptake Support Growth
globenewswire.com
ABT
BDX
BIIB
CHE
CTAS
CUE
DHR
DIA
EXPE
GEHC
GILD
HOLX
ICUI
ILMN
INCY
ISRG
LH
LULU
MRNA
NBIX
NOC
ORCL
PDD
PFE
QGEN
QDEL
REGN
ROKU
SNPS
TMO
TSLA
VRTX
XRAY
Incyte gibt positive CHMP-Stellungnahme zu Zynyz ® (Retifanlimab) für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) bekannt
businesswire.com
INCY
Incyte annuncia il parere favorevole del CHMP per Zynyz ® (retifanlimab) per il trattamento di prima linea del carcinoma anale squamocellulare (SCAC) in fase avanzata
businesswire.com
INCY
Incyte annonce un avis favorable du CHMP concernant Zynyz ® (retifanlimab) pour le traitement de première ligne du carcinome épidermoïde du canal anal (SCAC)
businesswire.com
INCY
Incyte anuncia una opinión positiva de Zynyz ® (retifanlimab) del CMUH para tratamiento de primera línea del carcinoma de células escamosas del canal anal avanzado
businesswire.com
INCY
Incyte kondigt positief CHMP-advies aan voor Zynyz ® (retifanlimab) voor de eerstelijnsbehandeling van gevorderd plaveiselcelcarcinoom van de anus (SCAC)
businesswire.com
INCY
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
businesswire.com
INCY
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
globenewswire.com
INCY